Characterization of readmission after allogeneic hematopoietic cell transplantation

Kyosuke Yamaguchi, Yoshihiro Inamoto, Kinuko Tajima, Kazuki Sakatoku, Masatomo Kuno, Akihisa Kawajiri, Tomonari Takemura, Takashi Tanaka, Ayumu Ito, Saiko Kurosawa, Sung Won Kim, Takahiro Fukuda

Research output: Contribution to journalArticlepeer-review


To elucidate the incidence, causes, and risk factors associated with readmission due to transplant-related complications, we studied 213 consecutive patients who were discharged without progression of primary disease after their first allogeneic hematopoietic cell transplantation at our center between 2013 and 2016. The median patient age was 50 years (range, 18–71 years). Eighty-three patients had AML or MDS, 66 had lymphoma, 28 had ALL, 23 had ATL, and 13 had other diseases. The median duration of hospitalization for transplantation was 56 days (range 27–325 days). The cumulative incidences of readmission due to transplant-related complications were 8% at 30 days, 16% at 100 days, and 25% at 1 year after discharge. The most frequent cause of readmission was infection, followed by graft-versus-host disease throughout the first year. In multivariate analysis, steroid use at discharge was the only risk factor associated with readmission within 30 days, and steroid use at discharge, absolute lymphocyte count < 500/µl at discharge, and documented bacterial infection during admission were risk factors associated with readmission within 1 year. Our results indicated that factors during hospitalization or discharge, but not at transplantation, were associated with readmission. Patients with these risk factors should be monitored carefully after discharge.

Original languageEnglish
Pages (from-to)1335-1340
Number of pages6
JournalBone Marrow Transplantation
Issue number6
Publication statusPublished - 06-2021
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation


Dive into the research topics of 'Characterization of readmission after allogeneic hematopoietic cell transplantation'. Together they form a unique fingerprint.

Cite this